Health at a Glance 2025: Egypt

This report benchmarks Egypt’s health system performance against OECD averages, detailing population health status, risk factors, and resource allocation. It provides essential comparative data on healthcare access, spending, and workforce capacity to help contextualize the country’s medical and regulatory environment.

Egypt: Health Profile

This interactive dashboard tracks Egypt’s vital health metrics, including life expectancy, primary causes of death, and disease risk factors like obesity and tobacco use. It provides essential context on healthcare spending and immunization coverage, helping benchmark the country’s public health performance against regional neighbors.

Chapter 37 – Drug safety in Egypt (ScienceDirect)

This book chapter from Patient Safety in Developing Countries provides a comprehensive overview of the historical and current state of medication safety in Egypt. It highlights that a formal medication safety system has been established in Egypt since 1995, detailing the subsequent regulatory frameworks that mandate robust pharmacovigilance systems nationwide and outline the responsibilities of the Egyptian Drug Authority in protecting patient health.

Pharmacovigilance Systems in Arab Countries: Overview

This cross-sectional review article maps out the current landscape and development levels of pharmacovigilance systems across the Arab world. The study categorizes Egypt—alongside countries like Saudi Arabia, Morocco, and Jordan—as having an advanced pharmacovigilance system, noting that while 45% of Arab nations are official members of the WHO’s monitoring centre, significant disparities in drug safety infrastructure still exist across the region.

Healthcare professionals’ knowledge and practice of and attitudes towards pharmacovigilance in Alexandria, Egypt 

This questionnaire-based study assesses the preparedness and awareness of healthcare professionals (such as pharmacists and physicians) regarding adverse drug reaction reporting in Alexandria. The findings generally reveal that while medical staff exhibit a positive attitude toward drug safety monitoring, their practical knowledge and actual reporting behaviors remain low, identifying a substantial gap between adverse events experienced by patients and those officially reported to regulatory bodies.

Guideline on Reliance Practices for Pharmacovigilance

Issued by the EDA’s Pharmaceutical Vigilance General Administration (PVGA), this document outlines how Egypt implements reliance strategies—meaning how the EDA utilizes the safety evaluations, decisions, and reports generated by other trusted international regulatory authorities to streamline the PV process in Egypt.

EDA Pharmacovigilance Inspection Annual Report

The EDA issues annual reports detailing the outcomes of their pharmacovigilance inspection activities. These reports serve to enhance transparency and regulatory oversight, providing statistical data on the number of pharmaceutical companies inspected and common compliance observations recorded during those inspections.